News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SIMCERE PHARMA's ENZESHU and ENDOSTAR Included in China's NRDL
SIMCERE PHARMA (02096.HK) announced that on December 7, 2025, ENZESHU (Suvemcitug for injection) has been officially included in the "Drugs Catalogue for the National Basic Me...
Reset
Send
The window will close in 5 seconds
SIMCERE PHARMA's ENZESHU and ENDOSTAR Included in China's NRDL
Close
Recommend
3
Positive
3
Negative
3
 
SHORT SELL
 
STOCK INFO

SIMCERE PHARMA (02096.HK)  -0.210 (-1.634%)    Short selling $1.70M; Ratio 5.972%   announced that on December 7, 2025, ENZESHU (Suvemcitug for injection) has been officially included in the "Drugs Catalogue for the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2025)" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, and will take effect from January 1, 2026. In addition, ENDOSTAR (Recombinant Human Endostatin for Injection) has also successfully completed the renewal under the National Reimbursement Drug List (NRDL).
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-12-17 12:25.)

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.